Front. Med. Frontiers in Medicine Front. Med. 2296-858X Frontiers Media S.A. 10.3389/fmed.2025.1647695 Original Research Coexisting genetic kidney disease explains many cases of ‘familial’ IgA nephropathy where the proband has biopsy-confirmed mesangial IgA deposits Li YuXin 1 † Data curation Methodology Writing – original draft Writing – review & editing Formal analysis Zhang Jing 1 † Formal analysis Investigation Methodology Writing – original draft Writing – review & editing Yin Zhuo Jun 1 † Data curation Investigation Methodology Writing – original draft Writing – review & editing Zhou Ziming 1 † Data curation Formal analysis Investigation Methodology Writing – original draft Writing – review & editing Huang Bocheng 1 † Data curation Formal analysis Investigation Methodology Writing – original draft Writing – review & editing Mahmood Khalid 2 Data curation Formal analysis Investigation Methodology Writing – original draft Writing – review & editing Colville Deb 3 Data curation Formal analysis Methodology Writing – original draft Writing – review & editing Barit David 4 Methodology Supervision Writing – original draft Writing – review & editing Auwardt Russell 5 Methodology Resources Supervision Writing – original draft Writing – review & editing Fassett Robert 6 Formal analysis Resources Supervision Writing – original draft Writing – review & editing Paizis Kathy 7 Resources Supervision Writing – original draft Writing – review & editing Ierino Francesco 7 Formal analysis Methodology Resources Writing – original draft Writing – review & editing Pianta Timothy 4 Data curation Formal analysis Resources Writing – original draft Writing – review & editing Langsford David 4 Resources Writing – original draft Writing – review & editing Huang Mary 1 Data curation Formal analysis Methodology Resources Writing – original draft Writing – review & editing Savige Judy 1 * Conceptualization Data curation Investigation Methodology Project administration Supervision Writing – original draft Writing – review & editing Department of Medicine, Melbourne Health and Northern Health, The University of Melbourne, Parkville, VIC, Australia Melbourne Bioinformatics, The University of Melbourne, Parkville, VIC, Australia Department of Surgery (Ophthalmology), Royal Victorian Eye and Ear Hospital, East Melbourne, VIC, Australia Renal Unit, Northern Health, Epping, VIC, Australia Renal Unit, Albury Hospital, Albury-Wodonga, VIC, Australia Tasmanian Health Service, North West, Burnie, TAS, Australia Department of Nephrology, Austin Health, Melbourne, VIC, Australia Correspondence: Judy Savige, jasavige@unimelb.edu.au

These authors share first authorship

 02 03 2026 2025 12 1647695 16 06 2025 28 12 2025 29 12 2025 Copyright © 2026 Li, Zhang, Yin, Zhou, Huang, Mahmood, Colville, Barit, Auwardt, Fassett, Paizis, Ierino, Pianta, Langsford, Huang and Savige. 2026 Li, Zhang, Yin, Zhou, Huang, Mahmood, Colville, Barit, Auwardt, Fassett, Paizis, Ierino, Pianta, Langsford, Huang and Savige https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Background

One in seven people with IgA nephropathy has another apparently-affected family member. This study examined how often biopsy-proven familial and sporadic IgA nephropathy were associated with genetic kidney disease.

 Methods

Eleven unrelated people with biopsy-proven IgA nephropathy and another family member with kidney tests compatible with IgA nephropathy were recruited. All available family members were assessed for genetic kidney disease, using Whole Exome Sequencing (WES). Their results were compared with those of 39 people with sporadic IgA nephropathy. All sequencing results were filtered for pathogenic variants in genes associated with genetic kidney disease (Genomics England panels, n = 384). Variants were assessed for pathogenicity using ClinVar and the ACMG/AMP criteria in Alamut.

 Results

Nine of the 11 probands (82%) with familial nephropathy and 30 of those with sporadic disease (77%) had kidney failure. At least five (45%) and possibly nine (82%) of the 11 families studied had disease-associated heterozygous variants consistent with a coexistent genetic kidney disease (autosomal dominant (AD) and X-linked (XL) Alport syndrome, ADTKD-HNF1B, and possibly Dent disease, Focal and Segmental Glomerulosclerosis (FSGS), and CHARGE syndrome). Inheritance for all these diseases was AD or X-linked. Sometimes the proband with IgA nephropathy did not have the genetic variant found in other apparently-affected family members. Sometimes two genetic variants corresponding to two different diseases were present in the same family. Two of the 39 people with sporadic IgA nephropathy (5%) also had disease-causing variants consistent with genetic kidney disease (AD Alport syndrome, cystinuria).

 Conclusion

Many familial cases of IgA nephropathy result from mesangial IgA deposition in the setting of coexisting genetic kidney disease. Sometimes, genetic kidney disease is not detected in the proband but is present in another family member. Individuals from families with IgA nephropathy should be offered genetic testing.

 Alport syndrome autosomal dominant familial hematuria familial kidney disease genetic kidney disease IgA nephropathy severe IgA nephropathy The author(s) declared that financial support was not received for this work and/or its publication. section-at-acceptance Nephrology Introduction

IgA nephropathy is possibly the commonest form of glomerulonephritis worldwide (1, 2). It is characterized by macroscopic hematuria associated with mucosal infections, and diffuse mesangial deposits of IgA, IgG, and C3. One in four of those affected develops kidney failure after 20 years (3), and IgA nephropathy accounts for 6% of patients requiring renal replacement therapy (4).

Our current understanding of the pathogenesis of IgA nephropathy includes ‘multiple hits.’ (5) Mucosal infections, including EBV (6) result in galactose-deficient IgA1 (7), which is targeted by anti-glycan IgG antibodies (8), forming immune complexes in the glomerular mesangium and activating complement by the alternative and lectin pathways (9). The diverse properties of these immune complexes (composition, molecular mass, etc.) may explain the presence or absence of symptomatology.

The evidence for genetic involvement in the pathogenesis of IgA nephropathy is complicated. Fifteen percent of people with biopsy-proven IgA nephropathy have another apparently-affected family member (10), often with disease in each generation. These familial forms of IgA nephropathy are typically more severe than sporadic disease, with earlier onset of kidney failure (11, 12). However, the familial association and increased severity are unexplained.

In IgA nephropathy, the abnormal mesangial IgA1 deposits are determined genetically by variants in the C1GALT1 gene (13). These variants likely contribute to the increased disease susceptibility in people of East Asian and Southern European ancestries (14). However, the effect of the C1GALT1 variants is unclear since only some family members with this change develop IgA nephropathy. Furthermore, while galactose-deficient mesangial IgA1 deposits are noted post-mortem in up to 20% of the population, many fewer people have an active glomerulonephritis (15–17).

Nevertheless, genetic variants that predispose to IgA nephropathy have been identified in potentially relevant pathways in various Genome Wide Association Studies (GWAS). These pathways affect mucosal innate immunity against pathogens (DEFA cluster, PADI4, IRF4, UBR5, CARD9, PSMB8/PSMB9, FCRL3); IgA1 production (TNFSF13, LIF, OSM) and glycosylation (ST6GAL1); antigen presentation (HLA cluster, PSMB8/PSMB9, TAP1/TAP2); lymphocyte maturation (DUSP22, VAV3); and complement activation (CFH, CFHR3-CFHR1, ITGAM, ITGAX) (18–21). HLA and additional genes have been implicated in IgA nephropathy and related diseases such as IgA vasculitis (formerly Henoch-Schonlein purpura) (22), Inflammatory Bowel Disease (23) and Ankylosing Spondylitis (24). In general, common variants in the GWAS-identified genes each have a small additive effect on disease risk, but rare deleterious variants in the same genes may have more pronounced consequences.

Finally, monogenic causes have been reported in some cases of familial IgA nephropathy. Affected genes include SPRY2, which encodes an inhibitor of B cell proliferation (25), as well as complement pathway genes (26, 27), and occasionally other apparently coincidental genetic kidney diseases (28–31). Up to 20% people with familial IgA nephropathy have been reported to have autosomal dominant (AD) or XL Alport syndrome, two of the most common genetic diseases affecting the kidney (32). Sometimes immunodeficiency genes are also associated with the development of autoimmune glomerulonephritis (33, 34).

This study examined how often familial causes were associated with an underlying genetic kidney disease, and differed from previous studies in that multiple family members were examined. These results were compared with those from people with sporadic IgA nephropathy.

 Participants and methods Participants

All 11 probands referred consecutively with familial IgA nephropathy from teaching hospitals between 2014 and 2022 were studied. Each family included at least one member with biopsy-proven disease and another person considered affected because of hematuria (>trace) or proteinuria (≥1+) on dipstick of freshly collected urine specimens (Ames, Germany), impaired kidney function (eGFR < 90 mL/min/1.73 m2) without another obvious cause, or biopsy evidence of IgA nephropathy. End-stage Kidney failure (eGFR<15 mL/min/1.73 m2; dialysis-dependence or a current kidney transplant) was noted. The renal biopsies themselves were not available for study.

Furthermore, 39 consecutive unrelated patients with biopsy-proven IgA nephropathy but without another affected family member with IgA nephropathy or kidney disease (‘sporadic’ cases) were also examined. People with a secondary cause of IgA nephropathy (e.g., liver disease, etc.) were excluded.

A further five people with biopsy-proven IgA vasculitis and nine with sporadic glomerulonephritis [lupus nephritis in eight; Focal and Segmental glomerulosclerosis (FSGS) in one] were also studied.

This project was approved by the Austin Health Human Research Ethics Committee (HREC/16/Austin/538) in accordance with the principles of the Declaration of Helsinki, and all participants provided written informed consent for their involvement.

 Whole exome sequencing and variant filtering

Participants provided peripheral blood from which DNA was extracted using a QIAamp DNA Blood Mini Kit (Qiagen, Netherlands) and 50 ng of purified DNA underwent Whole Exome Sequencing (WES) using libraries prepared with the SureSelect XT Clinical Research Exome v2 target enrichment kits (Agilent Technologies, CA, USA) on an Illumina NovaSeq platform (California) at the Australian Genome Research Facility, Melbourne. Germline single-nucleotide variants (SNV) and short insertions/deletions (indels) were called using standard workflows based on the Genome Analysis Toolkit (GATK v4.4.0) (35). The variants were annotated using the Ensembl Variant Effect Predictor tool (36).

Variants were filtered for changes in 384 genes from the Genomics England panels for genetic kidney disease (Hematuria, Renal proteinuria, CAKUT Cystic kidney disease, and Renal ciliopathies, Kidney failure with no obvious cause) (Supplementary Table S1).1 HLA variants were not examined.

Genetic variants were filtered to identify rare variants [<30 alleles in gnomAD v2.1.1 (37)] that were pathogenic or likely pathogenic according to ACMG/AMP criteria (38) in Alamut2 based on the in silico prediction tools, Polyphen2, SIFT, and Mutation Taster (39–41), or pathogenic or likely pathogenic in ClinVar.3 The scores provided were calculated automatically by Alamut. Scores of at least 5, or those classified as likely pathogenic or pathogenic in ClinVar, were also noted. Two pathogenic variants in the same person were required for the diagnosis of a biallelic kidney disease.

 Results Familial IgA nephropathy (11 families)

Eleven probands with familial IgA nephropathy and seven members of their families (median 4, range 2–9) were studied clinically and underwent WES (median 3, range 1–12) (Tables 1–3; Figures 1a–k). Nine families (82%) had at least one member with end-stage kidney failure.

Evaluation of likely pathogenic variants in genes for genetic kidney disease in people with familial IgA nephropathy, sporadic IgA nephropathy, IgA vasculitis, or other autoimmune forms of glomerulonephritis.

Family Gene Disease and mode of inheritance Sequence change Alleles in gnomAD (v.2.1) Alamut ClinVar
1D proband C9 AR predisposes to bacterial infections and autoimmune disease NM_001737.5:c.162C > A;NP_001728.1:p.Cys54Ter (het) 247 Pathogenic (PVS1, PM2, PP5) score = 11 Pathogenic/Likely pathogenic**; rs34000044
2I proband COL4A3 AD, Alport syndrome NM_000091.5: c.1184G > A;p.Gly395Glu (het) None Likely pathogenic (PM1, PM2, PP3,PP5) score = 6 Pathogenic/Likely pathogenic**; rs1131691738
3F proband COL4A5 XL Alport syndrome NM_033380.3:c.4149_4150del; NP203699.1:p.138ArgfsTer39 (het) None Pathogenic (PVS1, PM2)score = 10 Not found
Other members of 3F COL4A4 AD Alport syndrome NM_000092.5:c.2906C > G; NP_000083.3:p.Ser969Ter (het) 17 Pathogenic (PVS1, PM2, PP5),Score = 11 Pathogenic **; rs35138315
7M proband HNF1B AD, HNF1B-nephropathy NM_000458.4:c.1310C > T; NP_001291215.1:p.Pro437Leu (het) None VUS (PM2, PP5)score = 3 Likely pathogenic*
8H proband CHD7 AD, Charge syndrome NM_017780.4: c.3299G > A; P_060250.2:p.Arg1100His (het) 16 VUS (PM1, PM2, PP3) score = 5 Conflicting(Likely Benign or VUS)*;rs767259131
Other members of 11B INF2 FSGS NM_022489.4:c.*1 + 1G > C (het) 23 Pathogenic (PVS1, PM2)Score = 10 Conflicting* (VUS/Benign); Likely pathogenic46; rs758452999
Families where only the proband was tested
5U proband COL4A4 AD Alport syndrome NM_000092.5:c.1396G > A; NP_000083.3:p.Gly466Arg (het) 5 VUS (PM2, PP3, PP5) score = 4 Pathogenic/Likelypathogenic**;Rs:201859109
6C proband CLCN5 XL, Dent disease NM_001127899.4:c.1610G > A; NP_001121371.1:p.Arg537Gln (het) None VUS (PM1, PM2, PP3)Score = 5 Not found; not in HGMD
9M proband COL4A4 AD Alport syndrome NM_000092.5c. 1634G > T, p.Gly545Ala (het) 7,694 VUS (PM1, PM2,PP3) score = 5 VUS*; rs1800516
NPHS2 FSGS (risk factor) NM_014625.4c.686G > A,p.Arg229Gln (het) 4,448 VUS (PM1, BP4)Score = 1 Conflicting (P, LP, VUS, B);rs.61747728
10M proband COL4A5 XL Alport syndrome NM_033380.3:c.1871G > A: NP_203699.1:p.Gly624Asp (het) 16 Likely pathogenic (PM1, PM2, PP3,PP5) score = 6 Pathogenic/likely pathogenic**;Rs. 104,886,142
Individuals with sporadic IgA nephropathy (n = 39)
S1 COL4A3 AD Alport syndrome NM_000091.5: c.1855G > A P.Gly619Arg (het) 2 Pathogenic (PM1, PM2, PP3, PP5), score = 6 P/LP **;Rs.773515249
S47 SLC7A9 Cystinuria (AR and AD) NM_014270.5 c.997C > T, p.Arg333Trp (het) 24 Likely pathogenic (PM1, PM2, PP3, PP5) P/LP**;Rs.121908484
Individuals with IgA vasculitis (n = 5)
No pathogenic variants detected in genes studied
Individuals with other forms of glomerulonephritis (n = 9)
G19 SLC4A1 Distal renal tubular acidosis type 1, AD NM_000342.4 c.2102G > A, p.Gly701Asp (het) 10 Likely pathogenic (PM1, PM2, PP3, PP5) score = 6 Pathogenic**’ rs121912748

No disease-causing variant was found in family 4R.

* and ** refer to the ClinVar classification system; c.*1+1G>C refers to an upstream nucleotide variant G that has been substituted with C.

Clinical features, family members tested, and likely pathogenic variants in genetic kidney disease genes in the proband and family members with familial IgA nephropathy.

Family Proband (sex, age, ancestry) Clinical features in the proband with biopsy-proven IgA glomerulonephritis Total number of affected family members who were genetically tested Number of first-degree family members sequenced Pathogenic variant in the proband in the genetic kidney disease gene Pathogenic variant in affected family members
1D M, 46, N European Hematuria, proteinuria, kidney failure, transplant Four (brother also with biopsy-proven IgA disease, sister, niece) Eleven C9:p.Cys 24Ter C9 variant in proband, three affected, and one unaffected family member
2I M, 60, N European Hematuria, proteinuria Six (mother, uncle, cousin, sister, brother, daughter). Sister has a kidney transplant Ten p.Gly395Glu in COL4A3 (AD Alport syndrome) COL4A3 variant segregated with hematuria in the proband and five affected family members
3F M, 31, N European Hematuria, impaired kidney function Seven (father, grandfather, great uncle, three second cousins). Great uncle on dialysis Twelve p.Pro1384ArgfsTer39 in COL4A5 only in proband (XL Alport syndrome) COL4A5 variant in proband only; COL4A4 variant in great-uncle and two cousins. No pathogenic variant detected in the father or the grandfather of the proband
4R M, 60, N European Hematuria, proteinuria, impaired kidney function, and IgA vasculitis as a child Three (proband and two cousins) Five None None
5U F, 64, S European Hematuria, nearly normal kidney function One (daughter also affected) One p.Gly466Arg in COL4A4 LP (AD Alport syndrome) Family members were not examined
6C M, 51, N European Kidney failure, transplant One (sister affected mildly) One p.Arg537Gln in CLCN5 (XL Dent disease) Family members were not examined
7M M, 38, S European Hematuria, impaired kidney function Proband and two brothers (both on dialysis) Three p.Pro437Leu in HNF1B (HNF1B-nephropathy) HNF1B variant in all three affected brothers
8H M, 56, N European Hematuria, kidney failure, and a kidney transplant Two (a sister also had biopsy-proven IgA glomerulonephritis) Two p.Arg1100His in CHD7, c.3299G > A (AD Hypo-gonadotrophic hypogonadism 5 with or without anosmia, CHARGE syndrome) CHD7 variant in the affected male only
9M M, 55, N European Hematuria, impaired kidney function One (sister and mother also had hematuria) One p.Gly545Ala in COL4A4 (AD Alport syndrome);p.Arg229Gln in NPHP2 (FSGS) Family members not examined
10M M, 68, S European Hematuria, kidney failure at 60, kidney transplant One (mother, two daughters, and a grandson) was also affected One p.Gly624Asp in COL4A5 (XL Alport syndrome) Family members were not examined
11B M, 35, N European Hematuria, proteinuria, kidney failure, and kidney transplant Four (father, two sisters) Six None INF2: c.*1 + 1G > G (Pathogenic in HGMD) in the affected sister only

Clinical features and pathogenic variants in affected members of families with IgA nephropathy.

Family and family member Hematuria Proteinuria Impaired kidney function Renal biopsy Pathogenic variant
Family 1D
II-2 YES IgA gn p.Cys54Ter in C9
II-6 YES YES YES p.Cys54Ter in C9
II-8 (proband) YES YES YES (eGFR<20 mL/min/1.73 m2), Transplant IgA gn p.Cys54Ter in C9
III-5 YES NO NO p.Cys54Ter in C9
Family 2I
II-2 YES YES p.Gly395Glu in COL4A3
II-4 YES YES p.Gly395Glu in COL4A3
III-2 YES YES YES, Transplant IgA gn p.Gly395Glu in COL4A3
III-5 (proband) YES NO IgA gn p.Gly395Glu in COL4A3
III-7 YES p.Gly395Glu in COL4A3
IV-6 YES YES NO p.Gly395Glu in COL4A3
Family 3F
II-2 YES YES None detected
II-3 YES YES YES, Dialysis p.Ser969Ter in COL4A4
III-2 YES FSGS None detected
III-4 YES YES p.Ser969Ter in COL4A4
III-5 YES p.Ser969Ter in COL4A4
III-9 YES None detected
IV-1 (proband) YES YES IgA gn p.Pro138ArgfsTer39 in COL4A5
Family 4R
III-1 (proband) YES YES YES IgA vasculitis, Transplant None detected
III-4 YES None detected
III-5 YES None detected
Family 5U
I-1 (proband) YES NO NO IgA gn p.Gly466Arg in COL4A4
Family 6C
II-1 (proband) YES YES YES, Transplant IgA gn p.Arg537Gln in CLCN5
II-2 YES YES NO p.Arg537Gln in CLCN5
Family 7M
II-1 YES YES YES, Dialysis Diabetes, kidney cysts p.Pro437Leu in HNF1B
II-2 YES YES YES, Dialysis FSGS, diabetes, and kidney cysts p.Pro437Leu in HNF1B
II-3 (proband) YES YES YES IgA gn, diabetes, kidney cysts p.Pro437Leu in HNF1B
Family 8H
II-1 (proband) YES YES YES, Transplant IgA gn p.Arg1100His in CHD7
II-2 YES NO NO IgA gn None detected
Family 9M
II-1 (proband) YES NO NO IgA gn p.Gly545Ala in COL4A4, and p.Arg229Gln in NPHP2 (both of which are risk factors)
II-2 YES Not tested
Family 10M
II-1 (proband) YES YES YES, Transplant IgA gn p.Gly624Asp in COL4A5
III-2 YES Not tested
III-3 YES Not tested
IV-1 YES Not tested
Family 11B
I-1 YES YES YES None detected
II-1 (proband) YES YES YES, Transplant IgA gn None detected
II-2 YES YES YES FSGS c.*1 + 1G > C in INF2
II-4 YES None detected

Family trees of the patients studied here. (a–c) Families 1–3; (d–g) Families 4–7; (h–k) Families 8–11. The index case is indicated by an arrow, and all family members are indicated by generation and birth order. Those with features of kidney disease (hematuria, proteinuria, and impaired kidney function) are demonstrated by the filled squares or circles. Those with a star underwent whole exome sequencing.

Pedigree charts for eleven families labeled 1D to 11B. Each chart shows multiple generations with symbols indicating gender and shading to represent individuals affected by a trait. Arrows point to probands, with asterisks marking certain family members. Each family chart has variations in structure, affected individuals, and generational lines.

Of the 11 families studied, five (45%) had pathogenic variants previously associated with monogenic kidney diseases (2I, 3F, 5U, 7M, and 10M) (Tables 1, 2). Alport syndrome was found in the probands of four of these families (2I, 3F, 5U, and 10M), and the other had an HNF1B pathogenic variant and HNF1B-nephropathy.

Four further families (6C, 8H, 9M, and 11B) had interesting and possibly pathogenic variants, one additional family had two risk factors for kidney failure (9M), and one (1D) had a heterozygous variant in a gene (C9) previously associated with IgA nephropathy in the biallelic form.

Two of the families (3F and 11B) had members other than the proband who had a pathogenic (3F, p.Ser969Ter in COL4A4) or possible pathogenic variant (11B, c.1 + 1G > C in INF2) in genes affected in kidney disease (AD Alport syndrome, FSGS, respectively). Thus, this second variant in family 3F affected an Alport gene.

All disease-causing variants were heterozygous or hemizygous, rather than biallelic. Only two families (1D and 4R) had no suspected genetic kidney disease at all in the proband or a family member.

Families with genetic kidney disease

Five families had disease-causing variants. Four of the families had disease-causing variants in the Alport genes. Three families (2I, 5U, and 10M) each had one pathogenic variant in an Alport gene, and one (3F) had two pathogenic variants in Alport genes. The affected genes were COL4A5 in two families (X-linked Alport syndrome), and COL4A3 and COL4A4 (AD Alport syndrome) in the others.

Family 3F had p.Pro1384ArgTer39 in COL4A5 in the proband only, and three other 3F family members had a different heterozygous pathogenic variant (p.Ser969Ter in COL4A4) that was not present in the proband but segregated with hematuria. No family member had both variants. Proband 5U had a pathogenic variant in COL4A4 (p.Gly466Arg) an Alamut score of 4, but which was considered Pathogenic in ClinVar. Furthermore, Proband 9M had the p.Gly545Ala variant in COL4A4, which may be associated with hematuria and kidney failure (42), but is generally not considered pathogenic. It was found together with an NPHS2 variant (p.Arg229Gln) that results in FSGS in a biallelic disease and has been reported previously to worsen the effect of a monoallelic COL4A3 or COL4A4 variant (43, 44). Both the p.Gly545Ala in COL4A4 and p.Arg229Gln in NPHS2 are considered ‘risk factors’ for kidney failure but are not on their own associated with hematuria or proteinuria, respectively.

Furthermore, proband 7M had a heterozygous variant p.Pro437Leu in HNF1B, which, despite a pathogenicity score of 3 in Alamut, was considered likely pathogenic in ClinVar and consistent with the clinical phenotype of HNF1B-nephropathy in the patient and his two affected brothers, who all had diabetes, kidney cysts, infertility, and kidney failure.

 Families with possibly disease-causing variants

Proband 1D had a heterozygous pathogenic variant in C9, which has been associated previously in the biallelic form with IgA nephropathy (26). This variant was also found in three other affected and one unaffected family member. While there is currently no known role for the monoallelic form of this variant in the pathogenesis of IgA nephropathy, at least one person has been reported with a low but detectable C9 level (45). This suggests a heterozygous variant that was not confirmed genetically.

Proband 6C had a possible variant in CLCN5 (Dent disease), with a pathogenicity score of 5 in Alamut, and which was classified as a VUS. Inheritance for this gene is X-linked. The proband had developed kidney failure in his forties and his sister had hematuria and proteinuria, with mildly impaired kidney function but had not undergone WES. This variant was not present in ClinVar, LOVD, or HGMD. No more clinical details were available.

Proband 9M had variants in COL4A4 and NPHS2 (p.Gly545Ala, p.Arg229Gln, respectively) that are generally considered ‘risk factors’ for kidney failure rather than disease-causing, but the effect of the combination is unknown.

Proband 8H had a possibly pathogenic variant (p.Arg1100His) in the CHD7 gene for Hypogonadotrophic hypogonadism 5 with or without anosmia/ CHARGE syndrome (Coloboma, Heart defects, Choanal atresia, Growth restriction, Genital abnormalities, and Ear abnormalities), which had a pathogenicity score of 5 in Alamut and was classified as a VUS. The patient had reflux nephropathy and low testosterone levels consistent with the variant being pathogenic, but none of the other facial, ocular, or cardiac features of CHARGE syndrome.

The proband in family 11B who had a kidney transplant had no pathogenic variant demonstrated but his sister with proteinuria had the c.*1 + 1G > C variant in INF2 that was assessed as Pathogenic with a score of 10 in Alamut and as Conflicting in ClinVar (VUS and Benign). A review of genetic causes of the corresponding disease, Charcot–Marie–Tooth disease/FSGS, classified this variant as likely pathogenic (46). The sister’s clinical and renal biopsy features were consistent with FSGS.

 Sporadic IgA nephropathy (<italic>n</italic> = 39)

Thirty of the 39 individuals (77%) with sporadic IgA nephropathy had kidney failure, six (15%) had normal kidney function, and three (8%) had unknown kidney function.

Two (5%) had a heterozygous pathogenic variant consistent with genetic kidney disease (Table 3). These diseases were AD Alport syndrome (p.Gly619Arg in COL4A3); and AD Cystinuria (p.Arg333Trp in SLC7A9, Pathogenic/Likely pathogenic in ClinVar).

 IgA vasculitis (<italic>n</italic> = 5)

These included four individuals with childhood—and one with adult-onset disease, two of whom had kidney failure (40%). None had a pathogenic variant in a gene affected in genetic kidney disease (Table 3).

 Other autoimmune forms of glomerulonephritis (<italic>n</italic> = 9)

These included eight individuals with SLE and one with FSGS, where four (44%) had kidney failure, three (33%) had normal kidney function, and kidney function was unknown in two (22%). One person (11%) with normal kidney function had a heterozygous pathogenic SLC4A1 variant consistent with the diagnosis of AD Distal renal tubular acidosis type 1, and there were no other genetic kidney diseases (Table 3).

 Discussion

This study demonstrated that families with IgA nephropathy commonly have an underlying genetic kidney disease that explains the familial occurrence. At least five, and probably more, of the 11 families described here had a pathogenic variant in a kidney disease-causing gene. Four families had pathogenic variants in the Alport genes, and five different Alport variants were detected. Genetic kidney disease was also found in 5% of individuals with sporadic IgA nephropathy, which was much less common than in the families.

Genetic kidney disease was found more often in this study than reported previously, in part because family members were tested and sometimes had a pathogenic variant not present in the index case. Our cohort was unbiased since the probands were those referred consecutively with familial IgA nephropathy over the period of review. Underlying genetic kidney disease in familial IgA nephropathy is likely to be even more common than demonstrated here because WES was used for genetic testing but detects only 80% of pathogenic changes (47–49) and sometimes overlooks large deletions, deep splicing changes and variants in alternative disease-causing genes.

These observations suggest that the mesangial IgA deposits, which are normally present in 20% of the population, coexist with genetic kidney disease (15, 16) and contribute to the more severe clinical course seen in familial IgA nephropathy (11, 12).

The genetic kidney diseases identified in familial IgA nephropathy reflect the commonest seen, namely, AD and XL Alport syndrome, and AD Tubulointerstitial kidney disease (ADTKD) (48). Another common disease, AD Polycystic Kidney Disease, was probably excluded based on family history and renal imaging. However, additional pathogenic variants in ADTKD-HNF1B and ADTKD-MUC1 might have been missed because WES often does not recognize the large deletions that occur in HNF1B and the typical MUC1 frameshift mutations that require targeted testing.

None of the genetic diagnoses demonstrated here were suspected before testing. In particular, the cysts in Family 7M with ADTKD-HNF1B nephropathy were only recognized on reverse phenotyping. Our cohort included two males with XL Alport syndrome, but neither had the typical hearing loss nor ocular abnormalities. The COL4A5 p.Gly624Asp variant in Family 10M is associated with mild disease, late-onset kidney failure, and no extrarenal features. AD Alport syndrome was the commonest genetic diagnosis (32) but also was not associated with hearing loss or ocular abnormalities (50). Although the glomerular basement membrane is typically thinned in AD or lamellated in XL Alport syndrome, these features were not helpful diagnostically in this cohort. This was because electron microscopy of the kidney biopsy is not routinely performed in Australia; and in late stage kidney disease, the glomeruli are often too scarred to identify the membrane changes typical of Alport syndrome.

While each proband in the cohort had biopsy-proven IgA nephropathy, the diagnosis was often made clinically in other family members. In retrospect, the finding of hematuria, proteinuria, or impaired kidney function may have indicated a genetic kidney disease rather than IgA nephropathy. Indeed, this study found that the proband may have had IgA nephropathy but not the genetic disease present in other family members.

Familial IgA nephropathy is typically found in multiple members of a generation and in several generations, consistent with AD or XL inheritance. Our findings of coexisting genetic diseases with AD or XL inheritance were consistent with this. Autosomal recessive (AR) kidney diseases, such as FSGS, and the ciliopathies and tubulopathies, which are generally rarer, and more likely to occur sporadically, were not identified in this cohort. Any sex-based difference in severity may not be obvious with later onset disease and in families comprising mainly boys or affected females (51).

Genetic kidney disease occurred in 5% of our series of sporadic cases of IgA nephropathy, which was much less often than in familial disease. However, many sporadic cases also had kidney failure and a consequently increased risk of genetic disease (52). Coexisting genetic kidney disease was also present in a patient with autoimmune glomerulonephritis, but not in IgA vasculitis.

The prevalence of kidney failure in our cohorts of familial and sporadic IgA nephropathy may have increased the risk of genetic kidney disease, which occurs in up to 20% of those with kidney failure (52). Even AD Alport syndrome, where kidney function is typically normal, is associated with worse function in IgA nephropathy (11, 12).

IgA vasculitis was studied here because its mesangial IgA deposits resemble those found in IgA nephropathy, and its childhood onset suggested a genetic basis. However, no coexisting genetic kidney disease was found with IgA vasculitis, and an association with HLA type has been better substantiated (22).

The strengths of this study were the unbiased cohort with familial IgA nephropathy; the additional sequencing of members of most families; examination of a cohort with sporadic biopsy-proven IgA nephropathy; investigation of a large panel of genes associated with genetic kidney disease; and the use of rigorous filtering criteria and confirmation of pathogenicity in Alamut and ClinVar.

This study’s limitations were that many index cases had kidney failure, where genetic disease is more common anyway (52); clinical information, apart from hematuria, proteinuria and kidney failure, was limited and follow up was often incomplete; variants themselves were not confirmed independently with an alternate sequencing method; the original kidney biopsies were not available for further analysis, and in most cases the diagnosis of IgA nephropathy was made on a biopsy in one family member and presumed in others with kidney abnormalities. Further, pathogenic variants might have been overlooked because the regions of some genes were not adequately covered by WES.

In conclusion, many, and possibly most, familial IgA nephropathy results from IgA deposits and coexisting genetic kidney disease, especially the more common AD and XL Alport syndrome. Sometimes, genetic kidney disease is not detected in the proband but is present in another family member with IgA nephropathy. Genetic kidney disease also occurs in sporadic IgA nephropathy with kidney failure. Individuals with familial IgA nephropathy should be offered genetic testing, and family members should only be used as kidney donors if a genetic kidney disease has been excluded. Further, more sensitive testing may demonstrate that all cases of familial IgA nephropathy result from co-existing genetic kidney disease.

 Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

 Ethics statement

The studies involving humans were approved by the Austin Health Human Research Ethics Committee. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

 Author contributions

YL: Data curation, Methodology, Writing – original draft, Writing – review & editing, Formal analysis. JZ: Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. ZY: Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing. ZZ: Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. BH: Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. KM: Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing. DC: Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing. DB: Methodology, Supervision, Writing – original draft, Writing – review & editing. RA: Methodology, Resources, Supervision, Writing – original draft, Writing – review & editing. RF: Formal analysis, Resources, Supervision, Writing – original draft, Writing – review & editing. KP: Resources, Supervision, Writing – original draft, Writing – review & editing. FI: Formal analysis, Methodology, Resources, Writing – original draft, Writing – review & editing. TP: Data curation, Formal analysis, Resources, Writing – original draft, Writing – review & editing. DL: Resources, Writing – original draft, Writing – review & editing. MH: Data curation, Formal analysis, Methodology, Resources, Writing – original draft, Writing – review & editing. JS: Conceptualization, Data curation, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing.

 Acknowledgments

We would like to thank the patients and their clinicians who took part in these studies. We would also like to thank Genomics England for providing access to their gene panels for genetic kidney diseases, the hosts of the PP2, SIFT, and Mutation Taster websites, and Varsome. Bioinformatics analysis was performed in the Spartan computing cluster at the University of Melbourne with support from Melbourne Bioinformatics. This work was presented orally at the International Alport Workshop in Cyprus in March 2024.

 Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2025.1647695/full#supplementary-material

Candidate gene lists.

 References D'AmicoG. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. (1987) 64:709–27. SchenaFP NistorI. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. (2018) 38:435–42. doi: 10.1016/j.semnephrol.2018.05.013, 30177015 D'AmicoG. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. (2000) 36:227–37. doi: 10.1053/ajkd.2000.8966 ZhangL LiuX PascoeEM BadveSV BoudvilleNC ClaytonPA . Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: a multi-centre registry study. Nephrology. (2016) 21:387–96. doi: 10.1111/nep.12629, 26393772 SuzukiH KirylukK NovakJ MoldoveanuZ HerrAB RenfrowMB . The pathophysiology of IgA nephropathy. J Am Soc Nephrol. (2011) 22:1795–803. doi: 10.1681/ASN.2011050464, 21949093 KimCJ WooYJ KookH ChoiYY MaJS HwangTJ. Henoch-Schonlein purpura nephritis associated with Epstein-Barr virus infection in twins. Pediatr Nephrol. (2004) 19:247–8. doi: 10.1007/s00467-003-1387-7, 14677057 HikiY OdaniH TakahashiM YasudaY NishimotoA IwaseH . Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int. (2001) 59:1077–85. doi: 10.1046/j.1523-1755.2001.0590031077.x, 11231363 TomanaM NovakJ JulianBA MatousovicK KonecnyK MesteckyJ. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. (1999) 104:73–81. doi: 10.1172/JCI5535, 10393701 MatsudaM ShikataK WadaJ SugimotoH ShikataY KawasakiT . Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron. (1998) 80:408–13. doi: 10.1159/000045212, 9832639 ScolariF AmorosoA SavoldiS MazzolaG PratiE ValzorioB . Familial clustering of IgA nephropathy: further evidence in an Italian population. Am J Kidney Dis. (1999) 33:857–65. doi: 10.1016/s0272-6386(99)70417-8, 10213640 SatoY TsukaguchiH HigasaK KawataN InuiK LinhTNT . Positive renal familial history in IgA nephropathy is associated with worse renal outcomes: a single-center longitudinal study. BMC Nephrol. (2021) 22:230. doi: 10.1186/s12882-021-02425-8, 34147067 ShiM YuS OuyangY JinY ChenZ WeiW . Increased lifetime risk of ESRD in familial IgA nephropathy. Kidney Int Rep. (2021) 6:91–100. doi: 10.1016/j.ekir.2020.10.015, 33426388 LiGS ZhangH LvJC ShenY WangHY. Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int. (2007) 71:448–53. doi: 10.1038/sj.ki.5002088 KirylukK LiY Sanna-CherchiS RohanizadeganM SuzukiH EitnerF . Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. (2012) 8:e1002765. doi: 10.1371/journal.pgen.1002765, 22737082 WaldherrR RambausekM DunckerWD RitzE. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant. (1989) 4:943–6. doi: 10.1093/ndt/4.11.943 SuzukiK HondaK TanabeK TomaH NiheiH YamaguchiY. Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int. (2003) 63:2286–94. doi: 10.1046/j.1523-1755.63.6s.2.x, 12753320 VarisJ RantalaI PasternackA OksaH JanttiM PaunuES . Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol. (1993) 46:607–10. doi: 10.1136/jcp.46.7.607, 8157744 FeehallyJ FarrallM BolandA GaleDP GutI HeathS . HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol. (2010) 21:1791–7. doi: 10.1681/ASN.2010010076, 20595679 GharaviAG KirylukK ChoiM LiY HouP XieJ . Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. (2011) 43:321–7. doi: 10.1038/ng.787, 21399633 YuXQ LiM ZhangH LowHQ WeiX WangJQ . A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet. (2011) 44:178–82. doi: 10.1038/ng.1047, 22197929 KirylukK LiY ScolariF Sanna-CherchiS ChoiM VerbitskyM . Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. (2014) 46:1187–96. doi: 10.1038/ng.3118, 25305756 Lopez-MejiasR CastanedaS GenreF Remuzgo-MartinezS CarmonaFD LlorcaJ . Genetics of immunoglobulin-A vasculitis (Henoch-Schönlein purpura): an updated review. Autoimmun Rev. (2018) 17:301–15. doi: 10.1016/j.autrev.2017.11.024, 29353097 EllinghausD JostinsL SpainSL CortesA BethuneJ HanB . Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. (2016) 48:510–8. doi: 10.1038/ng.3528, 26974007 International Genetics of Ankylosing Spondylitis CCortesA HadlerJ PointonJP RobinsonPC KaraderiT . Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. (2013) 45:730–8. doi: 10.1038/ng.2667, MililloA La CarpiaF CostanziS D'UrbanoV MartiniM LanutiP . A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy. Eur J Hum Genet. (2015) 23:1673–8. doi: 10.1038/ejhg.2015.52, 25782674 YoshiokaK TakemuraT AkanoN OkadaM YagiK MakiS . IgA nephropathy in patients with congenital C9 deficiency. Kidney Int. (1992) 42:1253–8. doi: 10.1038/ki.1992.412, 1453611 MaillardN WyattRJ JulianBA KirylukK GharaviA Fremeaux-BacchiV . Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. (2015) 26:1503–12. doi: 10.1681/ASN.2014101000, 25694468 LiY GroopmanEE D'AgatiV PrakashS ZhangJ Mizerska-WasiakM . Type IV collagen mutations in familial IgA nephropathy. Kidney Int Rep. (2020) 5:1075–8. doi: 10.1016/j.ekir.2020.04.011, 32647767 StapletonCP KennedyC FennellyNK MurraySL ConnaughtonDM DormanAM . An exome sequencing study of 10 families with IgA nephropathy. Nephron. (2020) 144:72–83. doi: 10.1159/000503564, 31865346 LiuJW WangP HuangJ NieXJ ZhaoF ChenLZ . Genetic variants of familial hematuria associated genes in three families with hematuria with probands initially diagnosed as IgA nephropathy. Zhonghua Er Ke Za Zhi. (2019) 57:674–9. doi: 10.3760/cma.j.issn.0578-1310.2019.09.006, 31530352 PatersonAD LiuXQ WangK MagistroniR SongX KappelJ . Genome-wide linkage scan of a large family with IgA nephropathy localizes a novel susceptibility locus to chromosome 2q36. J Am Soc Nephrol. (2007) 18:2408–15. doi: 10.1681/ASN.2007020241, 17634434 GibsonJ FieldhouseR ChanMMY Sadeghi-AlavijehO BurnettL IzziV . Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol. (2021) 32:2273–90. doi: 10.1681/ASN.2020071065, 34400539 NagamineK PetersonP ScottHS KudohJ MinoshimaS HeinoM . Positional cloning of the APECED gene. Nat Genet. (1997) 17:393–8. doi: 10.1038/ng1297-393, 9398839 Finnish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet. (1997) 17:399–403. doi: 10.1038/ng1297-399 DePristoMA BanksE PoplinR GarimellaKV MaguireJR HartlC . A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. (2011) 43:491–8. doi: 10.1038/ng.806, 21478889 McLarenW GilL HuntSE RiatHS RitchieGR ThormannA . The Ensembl variant effect predictor. Genome Biol. (2016) 17:122. doi: 10.1186/s13059-016-0974-4, 27268795 KarczewskiKJ FrancioliLC TiaoG CummingsBB AlfoldiJ WangQ . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. (2020) 581:434–43. doi: 10.1038/s41586-020-2308-7, 32461654 RichardsS AzizN BaleS BickD DasS Gastier-FosterJ . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. (2015) 17:405–24. doi: 10.1038/gim.2015.30, 25741868 AdzhubeiIA SchmidtS PeshkinL RamenskyVE GerasimovaA BorkP . A method and server for predicting damaging missense mutations. Nat Methods. (2010) 7:248–9. doi: 10.1038/nmeth0410-248, 20354512 NgPC HenikoffS. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. (2003) 31:3812–4. doi: 10.1093/nar/gkg509, 12824425 SchwarzJM CooperDN SchuelkeM SeelowD. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. (2014) 11:361–2. doi: 10.1038/nmeth.2890 OzdemirF OygarDD BehlulA AtacS BardakS YukselisM Autosomal dominant tubulointerstitial kidney disease cosegregating with COL4A4:p.G545A in Turkish Cypriot families with kidney failure. doi: 10.21203/rs.3.rs2844330/v1 TonnaS WangYY WilsonD RigbyL TaboneT CottonR . The R229Q mutation in NPHS2 may predispose to proteinuria in thin-basement-membrane nephropathy. Pediatr Nephrol. (2008) 23:2201–7. doi: 10.1007/s00467-008-0934-7, 18726620 TsukaguchiH SudhakarA LeTC NguyenT YaoJ SchwimmerJA . NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest. (2002) 110:1659–66. doi: 10.1172/JCI16242 KandaE ShimamuraH TamuraH UchidaS TeradaY SakamotoH . IgA nephropathy with complement deficiency. Intern Med. (2001) 40:52–5. doi: 10.2169/internalmedicine.40.52, 11201372 VaethS ChristensenR DunoM LildballeDL ThorsenK VissingJ . Genetic analysis of Charcot-Marie-tooth disease in Denmark and the implementation of a next generation sequencing platform. Eur J Med Genet. (2019) 62:1–8. doi: 10.1016/j.ejmg.2018.04.003 BullichG Domingo-GallegoA VargasI RuizP Lorente-GrandosoL FurlanoM . A kidney-disease gene panel allows a comprehensive genetic diagnosis of cystic and glomerular inherited kidney diseases. Kidney Int. (2018) 94:363–71. doi: 10.1016/j.kint.2018.02.027, 29801666 Domingo-GallegoA PybusM BullichG FurlanoM Ejarque-VilaL Lorente-GrandosoL . Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players. Nephrol Dial Transplant. (2022) 37:687–96. doi: 10.1093/ndt/gfab019, 33532864 HortY SullivanP WeddL FowlesL StevanovskiI DevesonI . Atypical splicing variants in PKD1 explain most undiagnosed typical familial ADPKD. NPJ Genom Med. (2023) 8:16. doi: 10.1038/s41525-023-00362-z, 37419908 SavigeJ. Heterozygous pathogenic COL4A3 and COL4A4 variants (autosomal dominant Alport syndrome) are common, and not typically associated with end-stage kidney failure, hearing loss, or ocular abnormalities. Kidney Int Rep. (2022) 7:1933–8. doi: 10.1016/j.ekir.2022.06.001, 36090501 SavigeJ ColvilleD RheaultM GearS LennonR LagasS . Alport syndrome in women and girls. Clin J Am Soc Nephrol. (2016) 11:1713–20. doi: 10.2215/CJN.00580116, 27287265 GroopmanEE MarasaM Cameron-ChristieS PetrovskiS AggarwalVS Milo-RasoulyH . Diagnostic utility of exome sequencing for kidney disease. N Engl J Med. (2019) 380:142–51. doi: 10.1056/NEJMoa1806891, 30586318

Edited by: Gregory Papagregoriou, University of Cyprus, Cyprus

Reviewed by: Amir Shabaka, Hospital Universitario La Paz, Spain

Rohan Bhattacharya, Boston Children's Hospital and Harvard Medical School, United States

https://panelapp.genomicsengland.co.uk/

https://www.sophiagenetics.com/sophia-ddm-for-genomics/alamut-visual-plus/

https://www.ncbi.nlm.nih.gov/clinvar/